Abstract
Realization of part of clinical trial called: Randomized clinical multicenter study phase III trial comparing trastuzumab and taxane with Pertuzumab after treatment with anthracyclines and trastuzumab emtansin with Pertuzumab after anthracycline therapy as adjunctive therapy in patients with operable HER2 -positive primary breast cancer